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We retrospectively compared the transplantation outcomes for patients 50 years or older who received
umbilical cord blood transplantation (UCBT) with those who received unrelated bone marrow transplantation
(UBMT) for hematologic malignancies. A total of 1377 patients who underwent transplantation between 2000
and 2009 were included: 516 received 8/8 HLA allele-matched UBMT, 295 received 7/8 HLA allele-matched
UBMT, and 566 received 4/6 to 6/6 HLA-matched UCBT. Adjusted overall survival (OS) was signiﬁcantly
lower in those who underwent UCBT than those who underwent 8/8 HLAematched UBMT but was similar to
that of 7/8 HLAematched UBMT (the 2-year OS after 8/8 HLAematched UBMT, 7/8 HLAematched UBMT, and
UCBT were 49% [95% conﬁdence interval (CI), 45% to 55%], 38% [95% CI, 32% to 45%], and 39% [95% CI, 34% to
43%], respectively). However, adjusted OS was similar between 8/8 HLAematched UBMT and UCBT receiving
.84  105 CD34þ cells/kg among those with acute myeloid leukemia and those with acute lymphoblastic
leukemia (the 2-year OS was 49% [95% CI, 43% to 55%], and 49% [95% CI, 41% to 58%], respectively). These data
suggest that UCB is a reasonable alternative donor/stem cell source for elderly patients with similar outcomes
compared with UBM from 8/8 HLAematched unrelated donors when the graft containing .84  105 CD34þ
cells/kg is available.
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ty for Blood and Marrow Transplantation.cytogenetic abnormalities is higher in elderly patients with
acute myeloid leukemia (AML) or acute lymphoblastic leu-
kemia (ALL) than in younger patients, and overall survival
(OS) after intensive chemotherapy in elderly patients is
shorter than that in younger patients [1,2]. Inductions of
reduced-intensity and nonmyeloablative stem cell trans-
plantations allow elderly patients to receive allogeneic HSCT
[3,4], and these patients have increasingly received this type
of transplantation [5]. Only approximately 30% of patients
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have siblings who cannot serve as a donor because of their
age or underlying comorbidities; in such cases, an alternative
donor is needed.
HLA-matched unrelated bone marrow or peripheral
blood stem cells have been used as an alternative to an HLA-
identical sibling donor. Umbilical cord blood has been used
more frequently over the past decade, and several studies
andmeta-analyses have compared the outcomes of umbilical
cord blood transplantation (UCBT) with that of unrelated
bone marrow transplantation (UBMT) or unrelated periph-
eral blood stem cell transplantation (UPBSCT) [6-15]. How-
ever, the ﬁndings of those reports varied, and most of those
studies included a small number of elderly patients. To the
best of our knowledge, there has been no report that
compared the outcomes of elderly patients who received
UCBT with those who received UBMT or UPBSCT. Therefore,
the main objective of this study was to compare the out-
comes of patients 50 years or older who received UCBT with
those who received UBMT using the Japanese nationwide
registry data.
METHODS
Data Collection
Data regarding transplantations were extracted from the Transplant
Registry Uniﬁed Management Program system of the Japan Society for He-
matopoietic Cell Transplantation [16]. A total of 171 transplantation centers
performed unrelated HSCT for adults and reported transplantation data to
Japan Society for Hematopoietic Cell Transplantation between 2000 and
2009. All patients gave written informed consent at each transplantation
center. The trial was conducted in accordance with the Declaration of
Helsinki.
Patients with acute leukemia or myelodysplastic syndrome (MDS) who
were 50 years or older and who received unrelated HSCT between 2000 and
2009 were included. Because the bone marrow was exclusively harvested
from volunteer unrelated donors in Japan, cases of peripheral blood stem
cell transplantation were not included in this analysis. Only 7 patients
received double UCBT; therefore, these patients were also excluded. For the
bone marrow recipients, recipients whose HLA matched 8/8 or 7/8 with
their donor at the allelic level for HLA-A, HLA-B, HLA-C, and HLA-DRB1 were
included. For UCBT, recipients whose HLA matched 4/6 to 6/6 with their
donor at the antigen level for HLA-A and HLA-B and at the allelic level for
HLA-DRB1, and who received a single unit of umbilical cord blood con-
taining 2.0  107 or more total nucleated cells per kilogram of recipient’s
body weight at cryopreservation were included. Patients who had previ-
ously received autologous or allogeneic transplantation were excluded.
A myeloablative conditioning (MAC) regimen was deﬁned as a total
busulfan dose of more than 8 mg/kg, total melphalan dose of more than
140mg/kg, fractionated total body irradiation (TBI) of 8 Gy or more, or single
TBI of 5 Gy or more [17,18]. Other conditioning regimen was deﬁned as
reduced-intensity conditioning (RIC). Acute leukemia in the ﬁrst complete
remission (CR), refractory anemia with or without ringed sideroblasts, and
refractory cytopenia with multilineage dysplasia for MDS were deﬁned as
early phase; acute leukemia in the second or subsequent CR were deﬁned as
intermediate phase; and all other statuses were deﬁned as advanced phase.
The karyotype at diagnosis for AML, ALL, and MDS were classiﬁed as pre-
viously reported [2,19,20]. The year of transplantation was divided into 2
groups: 2000 to 2004 was deﬁned as the early period and 2005 to 2009 was
deﬁned as the recent period. Neutrophil recovery was deﬁned as the ﬁrst 3
consecutive days inwhich absolute neutrophil counts rose to greater than or
equal to 500/mm3. Acute graft-versus-host disease (GVHD) was evaluated
based on standard criteria [21]. Chronic GVHD was deﬁned according to the
classical classiﬁcation [22]. Relapse was deﬁned as disease recurrence
detected by hematological examination or detected by cytogenetic or mo-
lecular examination and requiring any treatment. Patients who did not
obtain CR after HSCT were deﬁned as patients who had a relapse the next
day after HSCT. Nonrelapse mortality (NRM) was deﬁned as death without
relapse. OS was deﬁned as the survival time from the date of transplantation
to death from any cause or the last follow-up.
Statistical Analysis
The demographic factors and disease characteristics were compared
between patients who underwent transplantation with 8/8 HLAematched
unrelated bone marrow, 7/8 HLAematched bone marrow, and umbilicalcord blood using Fisher’s exact test for the categorical data and the Mann-
Whitney U test for the continuous variables. OS was calculated from the
date of transplantation to death from any cause or last follow-up and was
estimated by the Kaplan-Meier method. Cox proportional hazards regres-
sion model was used for the multivariate analyses. Adjusted comparison of
the stem cell source on OS was performed using the Cox proportional
hazards regression model. Gray’s test was employed for the comparison of
cumulative incidence curves for relapse, NRM, neutrophil and platelet re-
coveries, and GVHD [23]. NRM and relapse were the competing event for
each other. For neutrophil and platelet recovery, death before neutrophil or
platelet recovery was the competing event; for GVHD, death without GVHD
was the competing event. Fine and Gray’s proportional hazard regression
model was employed for multivariate analyses with competing risks [24].
Multivariate analyses to compare the effect of stem cell source on trans-
plantation outcomes were performed with the consideration of other sig-
niﬁcant clinical variables in the ﬁnal models, which were built with the
signiﬁcant variables (P < .10) from the univariate analysis, which were then
deleted in a stepwise fashion from the model when a variable was not
statistically signiﬁcant (P > .05). The stem cell source was added in the ﬁnal
model. The following variables were considered: patient age at trans-
plantation, sex, primary disease (AML versus ALL versus MDS), karyotype at
diagnosis (favorable versus intermediate versus adverse), disease status at
transplantation (early phase versus intermediate phase versus advanced
phase), year of transplantation (early period versus recent period), condi-
tioning regimen (MAC versus RIC), use of TBI, and GVHD prophylaxis
(cyclosporine alone versus cyclosporine and other agent versus tacrolimus
alone versus tacrolimus and other agent versus other). All tests were
2-sided, and P < .05 was considered to indicate statistical signiﬁcance.
Analyses were performed with EZR version 1.20 (Saitama Medical Center,
Jichi Medical University) [25], which is a graphical user interface for R
version 3.0.2 (R Development Core Team, Vienna, Austria).
RESULTS
Patients and Transplantation Characteristics
Patients and transplantation characteristics are shown in
Table 1. A total of 1377 patients were included in this analysis,
and of those, 516 patients received 8/8 HLA allele-matched
UBMT, 295 patients received 7/8 HLA allelic-matched
UBMT, and 566 patients underwent transplantation from
4/6 to 6/6 HLAematched UCBT. The UCBT recipients were
signiﬁcantly older than the 8/8 or 7/8 HLAematched UBMT
recipients (P < .001), and more UCBT recipients underwent
RIC or nonmyeloablative transplantation (P < .001) and
received a TBI-containing conditioning regimen than did the
8/8 or 7/8 HLAematched UBMT recipients (P < .001). More
UCBT recipients had advanced phase disease (P < .001). Fe-
male donor tomale recipient transplantationwas included in
UCBT more than in UBMT (P < .001). Compared with those
receiving UBMT, more UCBT recipients had AML (P < .001)
and received GVHD prophylaxis with a single-agent regimen
(P < .001). The distribution of karyotype at diagnosis was
similar (Supplemental Tables 1e3). The distribution of re-
cipients’ sex and year of transplantation were similar among
the 3 groups. The median duration of follow-up for the sur-
viving patients who underwent transplantation with 8/8
HLAematched UBMT, 7/8 HLAematched UBMT, and 4/6 to 6/
6 HLA-matched UCBT was 23.7 months (range, 1.8 to 125.2
months), 18.6 months (range, 1.6 to 94.0 months), and 22.3
months (range, .1 to 107.5 months), respectively.
Hematopoietic Recovery
The median time from transplantation to neutrophil re-
covery in patients who underwent 8/8 HLAematched UBMT,
7/8 HLAematched UBMT, and 4/6 to 6/6 HLAematched UCBT
was 17 days (range, 1 to 100 days), 17 days (range, 4 to 169
days), and 24 days (range, 0 to 95 days), respectively.
Neutrophil recovery was faster in recipients with early phase
disease or intermediate phase disease than in those with
advanced phase disease (P < .001). MAC was an independent
negative predictor for neutrophil engraftment (P¼ .007). The
Table 1
Patients, Disease, and Transplantation Characteristics
Characteristic Total 8/8 HLAeMatched
Bone Marrow
7/8 HLAeMatched
Bone Marrow
Umbilical
Cord Blood
P Value
Number 1377 516 295 566
Sex (male) 816 (59%) 310 (60%) 188 (64%) 318 (56%) .091
Age, median (range), yr 57 (50-82) 56 (50-70) 57 (50-71) 58 (50-82) <.001
50-59 892 (65%) 376 (73%) 198 (67%) 318 (56%)
60-69 468 (34%) 138 (27%) 96 (33%) 234 (41%)
70 or older 17 (1%) 2 (<1%) 1 (<1%) 14 (3%)
Sex matching <.001
Female donor to male recipient 1030 (75%) 73 (14%) 67 (23%) 153 (27%)
Others 293 (21%) 443 (86%) 227 (77%) 360 (64%)
Unknown 54 (4%) 0 (0%) 1 (<1%) 53 (9%)
Body weight, median (range), kg 56 (32.0-102.4) 58.5 (32.0-102.4) 58.9 (35.1-92.0) 54.0 (32.0-86.0) <.001
Disease <.001
AML 902 (65%) 314 (61%) 180 (61%) 408 (72%)
ALL 244 (18%) 96 (19%) 47 (16%) 101 (18%)
MDS 231 (17%) 106 (20%) 68 (23%) 57 (10%)
Disease status at transplantation <.001
Early phase 471 (34%) 223 (43%) 94 (32%) 154 (27%)
Intermediate phase 221 (16%) 82 (16%) 58 (20%) 81 (14%)
Advanced phase 685 (50%) 211 (41%) 143 (48%) 331 (59%)
Year of transplantation
2000-2004 343 (25%) 128 (25%) 74 (25%) 141 (25%) 1
2005-2009 1034 (75%) 388 (75%) 221 (75%) 425 (75%)
Conditioning regimen
Myeloablative 653 (47%) 291 (56%) 147 (50%) 215 (38%) <.001
CY þ TBI (8 Gy) 174 (12%) 79 (15%) 43 (15%) 52 (9%)
CY þ TBI (8 Gy) þ other 135 (10%) 46 (9%) 19 (6%) 70 (13%)
BU þ CY 110 (8%) 64 (12%) 33 (12%) 13 (2%)
FLU þ BU (>8 mg/kg) 44 (3%) 34 (7%) 5 (2%) 5 (1%)
FLU þ BU (>8 mg/kg) þ TBI (<8 Gy) 40 (3%) 14 (3%) 7 (2%) 19 (3%)
FLU þ MEL (>140 mg/m2) 57 (4%) 28 (5%) 20 (7%) 9 (2%)
Other TBI-based regimen 66 (5%) 19 (4%) 13 (4%) 34 (6%)
Other BU-based regimen 27 (2%) 7 (1%) 7 (2%) 13 (2%)
RIC/NMA 712 (52%) 217 (42%) 145 (49%) 350 (62%)
FLU þ BU (8 mg/kg) 25 (2%) 5 (1%) 5 (2%) 15 (3%)
FLU þ BU (8 mg/kg) þ TBI (<8 Gy) 206 (15%) 91 (17%) 58 (20%) 57 (10%)
FLU þ BU (8 mg/kg) þ MEL (140 mg/m2) 26 (2%) 13 (3%) 5 (2%) 8 (1%)
FLU þ BU (8 mg/kg) þ other 33 (2%) 12 (2%) 16 (5%) 5 (1%)
FLU þ MEL (140 mg/m2) 64 (5%) 33 (6%) 16 (5%) 15 (3%)
FLU þ MEL (140 mg/m2) þ TBI (<8 Gy) 219 (16%) 33 (6%) 26 (9%) 160 (28%)
FLU þ MEL (140 mg/m2) þ TBI (<8 Gy) þ other 20 (2%) 3 (1%) 1 (<1%) 16 (3%)
FLU þ CY þ TBI (<8 Gy) 56 (4%) 3 (1%) 2 (1%) 51 (9%)
Other regimen including TBI (<8 Gy) 33 (2%) 13 (3%) 10 (3%) 10 (2%)
Other regimen not including TBI (<8 Gy) 30 (2%) 11 (2%) 6 (2%) 13 (2%)
Unknown 12 (1%) 8 (2%) 3 (1%) 1 (<1%)
TBI-containing conditioning regimen 962 (70%) 306 (59%) 184 (62%) 472 (83%) <.001
Addition of ATG to conditioning regimen 46 (3%) 17 (3%) 19 (6%) 10 (2%) .001
GVHD prophylaxis
CyA þ other 370 (27%) 129 (25%) 52 (18%) 189 (33%) <.001
CyA alone 68 (5%) 5 (1%) 3 (1%) 60 (11%)
TAC þ other 775 (56%) 359 (70%) 226 (76%) 190 (33%)
TAC alone 138 (10%) 15 (3%) 11 (4%) 112 (20%)
Others 13 (1%) 7 (1%) 3 (1%) 3 (1%)
None 13 (1%) 1 (<1%) 0 (0%) 12 (2%)
Total cell dose (range, 107/kg) 2.56 (2.00-5.62)
CD34þ cell dose (range, 105/kg) .83 (.01-14.02)
HLA-A, B, DR antigen level
Matched (6/6) 516 (100%) 295 (100%) 46 (8%)
One-antigen mismatched (5/6) 0 0 159 (28%)
Two-antigen mismatched (4/6) 0 0 361 (64%)
HLA indicates human leukocyte antigen; TBI, total body irradiation; GVHD, graft-versus-host disease; CY, cyclophosphamide; BU, busulfan; FLU, ﬂudarabine;
MEL, melphalan; NMA, nonmyeloablative; ATG, antithymocyte globulin; CyA, cyclosporine A; TAC, tacrolimus.
M. Tanaka et al. / Biol Blood Marrow Transplant 21 (2015) 517e525 519probability of neutrophil recovery by day 50 was signiﬁ-
cantly lower in recipients of 4/6 to 6/6 HLAematched UCBT
(72% [95% conﬁdence interval (CI), 68% to 75%]) than in those
of 8/8 HLAematched UBMT (95% [95% CI, 92% to 96%]) or 7/8
HLAematched UBMT (90% [95% CI, 85% to 93%]). On multi-
variate analysis, the 4/6 to 6/6 HLAematched UCBT was an
independent negative predictor for neutrophil engraftment
when compared with the 8/8 HLAematched UBMT (hazard
ratio [HR], .43 [95% CI, .38 to .50]; P < .001) and the 7/8HLAematched UBMT (HR, .47 [95% CI, .40 to .56]; P < .001)
(Table 2).
The probability of platelet recovery by day 180 was
also signiﬁcantly lower in the 4/6 to 6/6 HLAematched
UCB recipients (54% [95% CI, 50% to 58%]) than in those
who received the 8/8 HLAematched UBMT (83% [95% CI,
79% to 86%]) or the 7/8 HLAematched UBMT (75% [95% CI,
70% to 80%]). The median times from transplantation to
platelet recovery in the recipients of 8/8 HLAematched
Table 2
Multivariate Analysis of Transplantation Outcomes
Outcome HR (95% CI) P Value
Overall survival* Overall <.001
4/6-6/6eMatched UCB versus
8/8 HLAematched UBM
1.47 (1.24-1.74) <.001
4/6-6/6eMatched UCB versus
7/8 HLAematched UBM
1.03 (.86-1.24) .75
Relapsey Overall .02
4/6-6/6eMatched UCB versus
8/8 HLAematched UBM
1.35 (1.05-1.74) .02
4/6-6/6eMatched UCB versus
7/8 HLAematched UBM
1.18 (.89-1.56) .26
NRMz Overall .013
4/6-6/6eMatched UCB versus
8/8 HLAematched UBM
1.32 (1.06-1.64) .013
4/6-6/6eMatched UCB versus
7/8 HLAematched UBM
.98 (.77-1.25) .88
Neutrophil recoveryx Overall <.001
4/6-6/6eMatched UCB versus
8/8 HLAematched UBM
.42 (.37-.48) <.001
4/6-6/6eMatched UCB versus
7/8 HLAematched UBM
.47 (.40-.55) <.001
Platelet recoveryk Overall <.001
4/6-6/6eMatched UCB versus
8/8 HLAematched UBM
.36 (.30-.42) <.001
4/6-6/6eMatched UCB versus
7/8 HLAematched UBM
.44 (.37-.53) <.001
Grade II-IV acute GVHD{ Overall .36
4/6-6/6eMatched UCB versus
8/8 HLAematched UBM
1.10 (.89-1.36) .38
4/6-6/6eMatched UCB versus
7/8 HLAematched UBM
.69 (.56-.87) .001
Extensive chronic GVHD# Overall .022
4/6-6/6eMatched UCB versus
8/8 HLAematched UBM
.65 (.46-.92) .015
4/6-6/6eMatched UCB versus
7/8 HLAematched UBM
.56 (.38-.82) .003
UCB indicates umbilical cord blood; UBM, unrelated bone marrow.
* For overall survival, hazard ratio is adjusted with recipient age, sex,
primary disease, disease status at transplantation, and year of
transplantation.
y For relapse, hazard ratio is adjusted with primary disease, the use of TBI,
the use of antithymocyte globulin, and disease status at transplantation.
z For NRM, hazard ratio is adjusted with recipient sex, the use of TBI, and
year of transplantation.
x For neutrophil recovery, hazard ratio is adjusted with disease status at
transplantation, conditioning regimen, the use of TBI, and GVHD
prophylaxis.
k For platelet recovery, hazard ratio is adjusted with recipient sex, disease
status at transplantation, the use of TBI, year of transplantation, and GVHD
prophylaxis.
{ For grade II to IV acute GVHD, hazard ratio is adjusted with age, disease
status at transplantation, and the use of TBI.
# For extensive chronic GVHD, hazard ratio is adjusted with recipient sex.
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HLAematched UCBT were 29 days (range, 1 to 228 days),
32 days (range, 1 to 323 days), and 66 days (range, 8 to 230
days), respectively. Platelet recovery was also faster in re-
cipients with early phase disease or intermediate phase
disease than in those with advanced phase disease in (P <
.001). A 4/6 to 6/6 HLAematched UCBT was a strong in-
dependent negative predictor for platelet engraftment
within the multivariate analysis (versus 8/8 HLAematched
UBMT, HR, .36 [95% CI, .30 to .42]; P < .001, versus 7/8
HLAematched UBMT, HR, .44 [95% CI, .37 to .53]; P < .001,
respectively) (Table 2). MAC was not a negative predictor
for platelet engraftment.
GVHD
The cumulative incidence of grade II to IV acute GVHD by
100 days after transplantation was lower in recipients of an8/8 HLAematched UBMT (34% [95% CI, 30% to 39%]) than in
recipients of a 7/8 HLAematched UBMT (50% [95% CI, 44% to
56%]) or a 4/6 to 6/6 HLAematched UCBT (41% [95% CI, 36% to
45%]). More recipients who received a TBI-containing
regimen experienced grade II to IV acute GVHD by day 100
than did those who received a non-TBI regimen (43% [95% CI,
40% to 46%] versus 34% [95% CI, 29% to 39%], P ¼ .001). The 4/
6 to 6/6 HLAematched UCBT recipients had a similar risk of
grade II to IV acute GVHD to the 8/8 HLAematched UBMT
recipients within the multivariate analysis (HR, 1.10 [95% CI,
.89 to 1.36]; P ¼ .38) (Table 2). However, the 4/6 to 6/6
HLAematched UCBT recipients had a signiﬁcantly lower risk
of grade II to IV acute GVHD than did the 7/8 HLAematched
UBMT recipients (HR, .69 [95% CI, .56 to .87]; P ¼ .001)
(Table 2).
The cumulative incidence of the extensive type of chronic
GVHD by 2 years after transplantation was lower in re-
cipients of the 4/6 to 6/6 HLAematched UCB (15% [95% CI,
11% to 19%]) than in those who received the 8/8
HLAematched UBMT or 7/8 HLAematched UBMT (23% [95%
CI, 19% to 27%] and 25% [95% CI, 20% to 32%], respectively).
The same relationship was observed when performing the
multivariate analysis (versus 8/8 HLAematched UBMT, HR,
.65 [95% CI, .46 to .92]; P ¼ .015, versus 7/8 HLAematched
UBMT, HR, .56 [95% CI, .38 to .82]; P ¼ .003, respectively)
(Table 2).
Relapse
The cumulative incidence of relapse by 2 years was
signiﬁcantly higher in patients receiving the 4/6 to 6/6
HLAematched UCBT (26% [95% CI, 22% to 30%]) than in those
who received the 8/8 HLAematched UBMT (18% [95% CI, 15%
to 22%]) or those who received the 7/8 HLAematched UBMT
(21% [95% CI, 16% to 26%]). However, according to disease
status at transplantation, the relapse rate by 2 years after
the 8/8 HLAematched UBMT, 7/8 HLAematched UBMT, and
4/6 to 6/6 HLAematched UCBT were not statistically
different regardless of disease status at transplantation (8/8
HLAematched UBMT, 7/8 HLAematched UBMT, and 4/6 to 6/
6 HLAematched UCBT; early phase disease, 11% [95% CI, 7% to
16%], 15% [95% CI, 8% to 23%], and 19% [95% CI, 12% to 26%];
intermediate phase disease, 22% [95% CI, 13% to 32%], 26%
[95% CI, 15% to 39%], and 17% [95% CI, 10% to 27%]; advanced
phase disease, 35% [95% CI, 28% to 42%], 36% [95% CI, 28%
to 44%], and 43% [95% CI, 38% to 49%], respectively)
(Figure 1AeC). On multivariate analysis, the 4/6 to 6/6
HLAematched UCBT recipients had a signiﬁcantly higher risk
of relapse than did the recipients of the 8/8 HLAematched
UCBT (HR, 1.35 [95% CI, 1.05 to 1.74]; P ¼ .02) and had a
similar risk to that of the 7/8 HLAematched UBMT recipients
(HR, 1.18 [95% CI, .89 to 1.56]; P ¼ .26) (Table 2).
According to primary disease, the cumulative incidence of
relapse after the 4/6 to 6/6 HLAematched UCBT was higher
than that after the 8/8 HLAematched UBMT only in MDS
patients and was similar both in AML patients and in ALL
patients (Supplemental Table 4).
According to conditioning regimen, the cumulative
incidence of relapse after the 4/6 to 6/6 HLAematched
UCBT was higher than that after the 8/8 HLAematched
UBMT only in recipients of MAC (Supplemental Table 5).
Among the patients who received RIC, the cumulative
incidence of relapse after the 4/6 to 6/6 HLAematched
UCBT was signiﬁcantly higher than that after the UBMT in
recipients without extensive chronic GVHD. However, the
cumulative incidence of relapse after the 4/6 to 6/6
Figure 1. Cumulative incidence of relapse in patients with early phase disease, in those with intermediate phase disease, and in those with high-risk disease ac-
cording to hematopoietic stem cell source and donor-recipient HLA match. (A) The cumulative incidences of relapse in patients with early phase disease by 2 years
after an 8/8 HLAematched unrelated bone marrow transplantation (UBMT), a 7/8 HLAematched UBMT, and a 4/6 to 6/6 HLAematched umbilical cord blood
transplantation (UCBT) were 11% (95% CI, 7% to 16%), 15% (95% CI, 8% to 23%), and 19% (95% CI, 12% to 26%), respectively. (B) The cumulative incidences of relapse in
patients with intermediate phase disease by 2 years after an 8/8 HLAematched UBMT, a 7/8 HLAematched UBMT, and a 4/6 to 6/6 HLAematched UCBT were 22%
(95% CI, 13% to 32%), 26% (95% CI, 15% to 39%), and 17% (95% CI, 10% to 27%), respectively. (C) The cumulative incidences of relapse in patients with intermediate phase
disease by 2 years after an 8/8 HLAematched UBMT, a 7/8 HLAematched UBMT, and a 4/6 to 6/6 HLAematched UCBT were 35% (95% CI, 28% to 42%), 36% (95% CI, 28%
to 44%), and 43% (95% CI, 38% to 49%), respectively.
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after UBMT among the recipients of MAC (Supplemental
Figure 1).
NRM
The 2-year cumulative incidences of NRM after the 8/8
HLAematched UBMT, 7/8 HLAematched UBMT, and 4/6 to 6/
6 HLAematched UCBT were 32% (95% CI, 27% to 36%), 40%
(95% CI, 33% to 46%), and 38% (95% CI, 34% to 43%), respec-
tively. Among patients with early phase disease, the cumu-
lative incidence of NRM at 2 years after the 8/8
HLAematched UBMT was signiﬁcantly lower than that after
the 7/8 HLAematched UBMT or 4/6 to 6/6 HLAematched
UCBT (25% [95% CI, 19% to 32%], 35% [95% CI, 25% to 45%], and
37% [95% CI, 29% to 46%]) (Figure 2A). Among patients with
intermediate phase disease or advanced phase disease, NRM
by 2 years was not statistically different among 3 groups (8/8
HLAematched UBMT, 7/8 HLAematched UBMT, and 4/6 to 6/
6 HLAematched UCBT; intermediate phase disease; 32% [95%Figure 2. Cumulative incidence of NRM in patients with early phase disease, in thos
according to hematopoietic stem cell source and donor-recipient HLA match. (A) The
after an 8/8 HLAematched unrelated bone marrow transplantation (UBMT), a 7/8
transplantation (UCBT) were 25% (95% CI, 95% CI, 19% to 32%), 35% (95% CI, 95% CI, 2
cidences of NRM in patients with intermediate phase disease by 2 years after an 8/8 H
UCBT were 32% (95% CI, 31% to 43%), 27% (95% CI, 16% to 40%), and 28% (95% CI, 18%
advanced phase disease by 2 years after an 8/8 HLAematched UBMT, a 7/8 HLAematc
41% (95% CI, 32% to 50%), and 36% (95% CI, 30% to 41%), respectively.CI, 31% to 43%], 27% [95% CI, 16% to 40%], and 28% [95% CI, 18%
to 38%]; advanced phase disease, 34% [295% CI, 7% to 41%],
41% [95% CI, 32% to 50%], and 36% [95% CI, 30% to 41%],
respectively) (Figure 2B,C). On multivariate analysis, the 4/6
to 6/6 HLAematched UCBT recipients had a higher risk of
NRM than the 8/8 HLAematched UBMT recipients (HR, 1.32
[95% CI, 1.06 to 1.64]; P ¼ .013); however, they had a similar
risk to the 7/8 HLAematched UBMT recipients (HR, .98 [95%
CI, .77 to 1.25]; P ¼ .88) (Table 2). According to primary dis-
ease, NRM by 2 years after the 4/6 to 6/6 HLAematched UCBT
was likely higher than that after the 8/8 HLAematched
UBMT only among patients with MDS; however, the differ-
ence was not signiﬁcant regardless of primary diseases
(Supplemental Table 4). Onmultivariate analysis of subgroup
analysis according to conditioning regimen, NRM after the 8/
8 HLAematched UBMT was signiﬁcantly lower than that
after the 7/8 HLAematched UBMT and 4/6 to 6/6
HLAematched UCBT only among recipients of RIC
(Supplemental Table 5).e with intermediate phase disease, and in those with advanced phase disease
cumulative incidences of NRM in patients with early phase disease by 2 years
HLAematched UBMT, and a 4/6 to 6/6 HLAematched umbilical cord blood
5% to 45%), and 37% (95% CI, 29% to 46%), respectively. (B) The cumulative in-
LAematched UBMT, a 7/8 HLAematched UBMT, and a 4/6 to 6/6 HLAematched
to 38%), respectively. (C) The cumulative incidences of NRM in patients with
hed UBMT, and a 4/6 to 6/6 HLAematched UCBT were 34% (95% CI, 27% to 41%),
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The 2-year unadjusted probabilities of OS after the 8/8
HLAematched UBMT (51% [95% CI, 46% to 56%]) were
signiﬁcantly higher than those of the 7/8 HLAematched
UBMT (39% [95% CI, 32% to 45%]) and 4/6 to 6/6
HLAematched UCBT (35% [95% CI, 31% to 39%]) recipients,
respectively. The adjusted probabilities of OS at 2 years
were also signiﬁcantly better in recipients of the 8/8
HLAematched UBMT than in the recipients of the 7/8
HLAematched UBMT or 4/6 to 6/6 HLAematched UCBT (49%
[95% CI, 44% to 54%], 38% [95% CI, 32% to 45%], 39% [95% CI,
35% to 44%], respectively). This ﬁnding was also observed in
the subgroup analysis for disease status (at early phase: the
adjusted probabilities of OS at 2 years after the 8/8
HLAematched UBMT, 7/8 HLAematched UBMT, and 4/6 to 6/
6 HLAematched UCBT were 69% [95% CI, 62% to 76%], 54%
[95% CI, 44% to 66%], and 46% [95% CI, 38% to 56%]; at in-
termediate phase: 53% [95% CI, 42% to 67%], 55% [95% CI, 42%
to 72%], and 62% [95% CI, 52% to 74%], respectively; at
advanced phase: 31% [95% CI, 24% to 39%], 24% [95% CI, 17% to
33%], and 25% [95% CI, 21% to 31%], respectively) (Figure 3).
According to the multivariate analysis, the 4/6 to 6/6
HLAematched UCBT recipients had a signiﬁcantly higher risk
of overall mortality than did the 8/8 HLAematched UBMT
recipients (HR, 1.47 [95% CI, 1.24 to 1.74]; P < .001) (Table 2).
However, the 4/6 to 6/6 HLAematched UCBT recipients had a
similar risk of overall mortality when compared with the 7/8
HLAematched UBMT recipients (HR, 1.03 [95% CI, .86 to
1.24]; P ¼ .75) (Table 2). The adjusted probabilities of OS at 2
years after 8/8 HLAematched UBMT were superior to those
after 4/6 to 6/6 HLAematched UCBT, regardless of primary
disease and conditioning regimen, especially in the patients
with MDS (Supplemental Figure 2, Supplemental Tables 4
and 5).
To identify the population of UCBT recipients who had a
similar OS to those of 8/8 HLAematched UBMT, we evaluated
the impact of cell dose, HLA matching, and GVHD prophy-
laxis on the OS of UCBT recipients. The 2-year unadjusted OS
of UCBT recipients who received .84  105 CD34þ cells/kg,
which was median cell dose, was signiﬁcantly higher
than those who received <.84  105 CD34þ cells/kg
(Supplemental Figure 3A). HLA matching did not have an
effect on OS (Supplemental Figure 3B). GVHD prophylaxisFigure 3. Adjusted probabilities of OS in patients with early phase disease, in those
according to hematopoietic stem cell source and donor-recipient HLA match. (A) The
early phase disease who received an 8/8 HLAematched unrelated bone marrow trans
umbilical cord blood transplantation (UCBT) were 69% (95% CI, 62% to 76%), 54% (95
probabilities of the 2-year OS after transplantation in patients with intermediate phase
and a 4/6 to 6/6 HLAematched UCBT were 53% (95% CI, 42% to 67%), 55% (95% CI, 42% t
of the 2-year OS after transplantation in patients with intermediate phase disease who
6/6 HLAematched UCBT were 31% (95% CI, 24% to 39%), 24% (95% CI, 17% to 33%), anwith calcineurin inhibitor (CNI) and other agents improved
OS compared with that with CNI alone (Supplemental
Figure 3C). Therefore, we compared the OS of 4/6 to 6/6
HLAematched UCBT recipients who received umbilical
cord blood units containing .84  105 CD34þ cells/kg with
8/8 HLAematched UBMT recipients, among those with
AML and those with ALL who received GVHD prophylaxis
with CNI and other agent. The unadjusted 2-year OS after
8/8 HLAematched UBMT was higher than 4/6 to 6/6
HLAematched UCBT in patients with early phase disease.
Among those with intermediate phase disease, the unad-
justed 2-year OS after 4/6 to 6/6 HLAematched UCBT was
likely higher than 8/8 HLAematched UBMT. Among those
with advanced phase disease, the 2-year OS were similar
between 2 groups (8/8 HLAematched UBMT versus 4/6 to 6/
6 HLAematched UCBT; the unadjusted OS of early phase
disease, 67% [95% CI, 59% to 74%] versus 55% [95% CI, 40% to
67%], P ¼ .044; the unadjusted OS of intermediate disease,
52% [95% CI, 39% to 64%] versus 77% [95% CI, 56% to 89%], P ¼
.08; the unadjusted OS of advanced phase disease, 25% [95%
CI, 17% to 33%] versus 26% [95% CI, 16% to 36%], P ¼ .82)
(Figure 4A,C). The adjusted probability of OS were similar
between 2 groups (8/8 HLAematched UBMT versus 4/6 to
6/6 HLAematched UCBT; the adjusted OS, 49% [95% CI, 43% to
55%] versus 49% [95% CI, 41% to 58%], P ¼ .74, respectively)
(Figure 4D).
DISCUSSION
The primary objectives of this study were to compare
OS after 4/6 to 6/6 HLAematched UCBT with those after 8/8
and 7/8 HLAematched UBMT in patients with hematologic
malignancies ages 50 years or older and to provide useful
data for the selection of an appropriate unrelated stem cell
source for those patients who do not have an available HLA-
identical sibling. Our ﬁndings suggested that an 8/8 HLA
alleleematched unrelated donor is the best alternative to a
HLA-identical sibling donor. Four of 6 to 6/6 HLAematched
UCBT had a similar OS to 8/8 HLAematched UBMT for pa-
tients with AML and for those with ALL when the umbilical
cord blood unit containing .84  105 CD34þ cells/kg is
available.
Neutrophil and platelet recovery were signiﬁcantly
slower after the 4/6 to 6/6 HLAematched UCBT than after thewith intermediate phase disease, and in those with advanced phase disease
adjusted probabilities of the 2-year OS after transplantation in patients with
plantation (UBMT), a 7/8 HLAematched UBMT, and a 4/6 to 6/6 HLAematched
% CI, 44% to 66%), and 46% (95% CI, 38% to 56%), respectively. (B) The adjusted
disease who received an 8/8 HLAematched UBMT, a 7/8 HLAematched UBMT,
o 72%), and 62% (95% CI, 52% to 74%), respectively. (C) The adjusted probabilities
received an 8/8 HLAematched UBMT, a 7/8 HLAematched UBMT, and a 4/6 to
d 25% (95% CI, 21% to 31%), respectively.
Figure 4. OS in UCBT recipient who received  .84  105/kg CD34 cells compared with 8/8 HLAematched UBMT recipients, among those with AML and ALL who
prevented graft-versus-host disease with CNI and other agents. (A) The unadjusted probabilities of the 2-year OS after transplantation in patients with acute myeloid
leukemia (AML) and acute lymphoblastic leukemia (ALL) at early phase disease and prevented GVHD with CNI and other agent who received an 8/8 HLAematched
unrelated bone marrow transplantation (UBMT) and a 4/6 to 6/6 HLAematched umbilical cord blood transplantation (UCBT) receiving .84  105/kg CD34 cells were
67% (95% CI, 59% to 74%) and 55% (95% CI, 40% to 67%), respectively, P ¼ .044. (B) The unadjusted probabilities of the 2-year OS after transplantation in patients with
AML and ALL at intermediate phase disease and prevented GVHD with CNI and other agent who received an 8/8 HLAematched UBMT and a 4/6 to 6/6 HLAematched
UCBT receiving .84  105/kg CD34 cells were 52% (95% CI, 39% to 64%) and 77% (95% CI, 56% to 89%), respectively, P ¼ .08. (C) The unadjusted probabilities of the
2-year OS after transplantation in patients with AML and ALL at advanced phase disease and prevented GVHD with CNI and other agent who received an 8/8
HLAematched UBMT and a 4/6 to 6/6 HLAematched UCBT receiving .84  105/kg CD34 cells were 25% (95% CI, 17% to 33%) and 26% (95% CI, 16% to 36%),
respectively, P ¼ .82. (D) The adjusted probabilities of the 2-year OS after transplantation in patients with AML and ALL prevented GVHD with CNI and other agent
who received an 8/8 HLAematched UBMT and a 4/6 to 6/6 HLAematched UCBT receiving .84  105/kg CD34 cells were 49% (95% CI, 43% to 55%) and 49% (95% CI, 41%
to 58%), respectively, P ¼ .74.
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ﬁndings from previous studies [6-9,11,15]. Neutrophil re-
covery in patients with early phase disease and intermediate
phase disease at transplantationwas signiﬁcantly faster than
in those with advanced phase disease, which was consistent
with the ﬁndings in allogeneic peripheral blood stem cell
transplantation that had been previously reported [26]. This
may be associated with the fact that patients with advanced
phase diseasewere likely pretreatedmore heavily than those
with early phase disease and intermediate phase disease and
that they had damage in the microenvironment of the bone
marrow.
UCBT recipients had a lower risk of extensive chronic
GVHD and a higher risk of relapse compared with 8/8HLAematched UBMT recipients. These ﬁndings suggested
that the graft-versus-leukemia effect in the UCBT recipients
was lower than that in the recipients of 8/8 HLAematched
UBMT.
Several studies comparing transplantation outcomes after
UBMT versus after UCBT have been reported [6-9]. In some
studies, serological HLA class I typing was used for UBMT
[6-8]. In another study, UCBT recipients were signiﬁcantly
younger than UBMT recipients, and all patients received a
MAC regimen. As a result, only a small number of patients
aged 50 years or older were included [9], so direct compar-
isons of our ﬁndings with previous studies are difﬁcult. We
had previously demonstrated that HR of overall mortality
after a 4/6 to 6/6 HLAematched UCBT was signiﬁcantly
M. Tanaka et al. / Biol Blood Marrow Transplant 21 (2015) 517e525524higher than that after an 8/8 HLAematched UBMT among
AML patients but not among ALL patients [15]. By contrast,
this study showed that the overall survival after an 8/8
HLAematched UBMT was superior to that after a 4/6 to 6/6
HLAematched UCBT for patients with AML and for patients
with ALL. The present study included patients 50 years or
older who received HSCT between 2000 and 2009 regardless
of intensity of the conditioning regimen, whereas our pre-
vious study had included the recipients of MAC between
2000 and 2005 ages 16 years or older. Therefore, 20% of the
8/8 HLAematched UBMT recipients and 10% of the 4/6 to 6/6
HLAematched UCBT recipients in the present study were
also included in our previous study. The discrepancy of the
results for ALL may be partly due to differences in condi-
tioning regimens (only recipients of MAC regimens were
described in our previous report, whereasmore than one half
of the patients in this study received RIC regimen). Older
patients with ALL had a higher risk of relapse and tended to
receive RIC when compared with younger patients [27];
therefore, these patients would need a strong graft-versus-
leukemia effect. In addition, short-term methotrexate im-
proved OS in the UCBT recipients [28]. In our cohort,
approximately 30% of UCBT recipients received GVHD pro-
phylaxis with cyclosporine or tacrolimus alone, and this
reduced OS in UCBT recipients. As previously described [29],
UCBT recipients receiving higher CD34þ cells had a higher OS
than those receiving lower CD34þ cells. For patients with
AML and for patients with ALL, UCBT recipients receiving
.84  105 CD34þ cells/kg had a similar adjusted and un-
adjusted OS to 8/8 HLAematched UBMT recipients. These
ﬁndings suggest that the outcomes of UCBT may improve
with graft selection based on CD34þ cell dose. The HR of
overall mortality after a 4/6 to 6/6 HLAematched UCBT was
similar to that after a 7/8 HLAematched UBMT, regardless of
disease status at transplantation. To the best of our knowl-
edge, this is the ﬁrst report to compare transplantation
outcomes in patients 50 years or older who received a 4/6 to
6/6 HLAematched UCBT with those who received a 7-8/8
HLAematched UBMT in a large cohort.
This study had several limitations. Although we adjusted
for known risk factors using multivariate analysis, we could
not exclude selection bias because this was a retrospective
study based on registry data. Further, donor selection was
inﬂuenced by several factors that were not statistically
adjustable. Some patients with urgent disease who could not
wait for the preparation of UBMT received UCBT; in other
cases, a suitable UCB unit with enough cell doses was not
available, and these patients therefore received UBMT. Pa-
tients who planned to receive UBMT and could not receive
transplantation because of disease progression during the
donor coordination were not included in this analysis. In
addition, only 5% of recipients of UBMT received GVHD
prophylaxis using only a CNI; on the other hand, approxi-
mately 30% of UCBT recipients employed the same protocol,
which may have inﬂuenced the occurrence of GVHD and
overall survival. A randomized controlled trial comparing
UCBT with UBMT is needed to validate the ﬁndings from the
present study; however, a study of that design is very difﬁ-
cult to conduct. Clinical decision analysis may help to address
any selection bias caused by the donor search process. From
2000 onwards, UPBSCT was more common than UBMT [5];
however, we could not compare the transplantation out-
comes of the 4/6 to 6/6 HLAematched UCBTwith the UPBSCT
because more than 99% of the unrelated donors from Japan
Marrow Donor Program were harvested bone marrow. Arandomized controlled trial comparing UPBSCT with UBMT
had shown similar outcomes for OS, NRM, and relapse rate
[30]. Taken together, UCBT may also be an alternative stem
cell source when a HLA-matched peripheral blood stem cell
donor is not available.
In conclusion, UCB is a reasonable alternative donor/stem
cell source for elderly patients with AML and for those with
ALL with similar outcomes compared with UBM from a 8/8
HLAematched unrelated donor when UCB unit containing
.84105 CD34þ cells/kg is available. If urgently needed or if
there is no 8/8 HLAematched unrelated donor, a 4/6 to 6/6
HLAematched UCBT is an acceptable treatment.ACKNOWLEDGMENTS
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